NIH CLINICAL TRIAL
Relapsed/Refractory B-Cell Malignancies

Investigating NX-2127, a BTK Degrader, in B-cell Malignancies

Researchers at the National Institutes of Health (NIH) are testing NX-2127, an oral drug that degrades a protein in cancer cells called Bruton's tyrosine kinase (BTK), instead of inhibiting or blocking it like other drugs. NX-2127 may also stimulate your immune T-cells to attack the cancer.

Study Includes:

- Taking NX-2127 by mouth daily for 28-day cycles
- Diagnostic procedures such as blood tests, bone marrow biopsies and CT scans (or PET-CT's as appropriate), lymph node biopsies, EKG, and echocardiogram
- Weekly outpatient visits during the first 8 weeks, and then approximately every 4 weeks after that

Location

NIH Clinical Center
America's Research Hospital
Bethesda, Maryland on the
Metro Red Line (Medical Center Stop)

NIH...Turning Discovery Into Health®

Eligible Participants:

- Are 18 years or older
- Are diagnosed with a B-cell malignancy as listed below
- Have relapsed after at least two prior systemic therapies for:
  - Chronic Lymphocytic Leukemia (CLL)
  - Small Lymphocytic Lymphoma (SLL)
  - Waldenström Macroglobulinemia (WM)
    (for WM, only one previous treatment required for participation)
  - Mantle Cell Lymphoma (MCL)
  - Marginal Zone Lymphoma (MZL)
  - Follicular Lymphoma (FL)
  - Diffuse Large B-cell Lymphoma (DLBCL)

National Heart, Lung, and Blood Institute

Contact Us!

Office of Patient Recruitment
800-411-1222/TTY users dial 7-1-1
ccopr@nih.gov
Ask for study # 000326-H

https://go.usa.gov/xuPDr